Table 2.
Effect of antidepressant use on subsequent development of IBD activity and according to anxiety and depression scores at baseline.
|
Antidepressant
Use: All Patients |
Antidepressant
Use: Normal Anxiety and Depression Scores at Baseline |
Antidepressant Use: Abnormal Anxiety or Depression Scores at Baseline |
Antidepressant Use: Abnormal Anxiety Scores at Baseline |
Antidepressant Use: Abnormal Depression Scores at Baseline |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No | Yes | P value | No | Yes | P value | No | Yes | P value | No | Yes | P value | No | Yes | P value | |
| Glucocorticosteroid prescription or flare of disease activity (%) | 121/279 (43.4) |
21/52 (40.4) |
0.69 | 82/203 (40.4) |
10/25 (40.0) |
0.97 | 38/73 (52.1) |
11/27 (40.1) |
0.32 | 35/65 (53.8) |
10/26 (38.5) |
0.19 | 9/21 (42.9) | 6/14 (42.9) | 1.00 |
|
| |||||||||||||||
| Escalation of medical therapy in response to uncontrolled disease activity (%) | 120/279 (43.0) |
17/52 (32.7) |
0.17 | 85/203 (41.9) |
10/25 (40.0) |
0.86 | 34/73 (46.6) |
7/27 (25.9) | 0.06 | 31/65 (47.7) |
6/26 (23.1) | 0.03 | 8/21 (38.1) | 5/14 (35.7) | 0.89 |
|
| |||||||||||||||
| Hospitalisation due to disease activity (%) | 38/279 (13.6) |
5/52 (9.6) |
0.43 | 26/203 (12.8) |
4/25 (16.0) | 0.66 | 12/73 (16.4) |
1/27 (3.7) |
0.09 | 11/65 (16.9) |
1/26 (3.8) |
0.10 | 2/21 (9.5) |
0/14 (0) |
0.23 |
|
| |||||||||||||||
| Intestinal resection (%) | 15/279 (5.4) |
4/52 (7.7) |
0.51 | 8/203 (3.9) |
3/25 (12.0) | 0.08 | 7/73 (9.6) |
1/27 (3.7) |
0.34 | 6/65 (9.2) |
1/26 (3.8) |
0.38 | 2/21 (9.5) |
0/14 (0) |
0.23 |
|
| |||||||||||||||
| Any adverse outcome (%) | 148/279 (53.0) |
24/52 (46.2) |
0.36 | 102/203 (50.2) |
12/25 (48.0) |
0.83 | 45/73 (61.6) |
12/27 (44.4) |
0.12 | 42/65 (64.6) |
11/26 (42.3) |
0.05 | 10/21 (47.6) |
6/14 (42.9) | 0.78 |